Drug recall · June 8, 2016
Ceftriaxone Sodium recall
Why: CGMP Deviations: active pharmaceutical ingredient intermediates failed specifications.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Ceftriaxone Sodium (Sterile) USP active pharmaceutical ingredient, DMF No. 15931; Manufactured by: Lupin Limited, Unit-1, 198-202, New Industrial Area No. 2, Dist. Raisen, Mandideep-462 046, (Madhya Pradesh) India; Regd. Office: 159, CST Road Kalina, Santacruz (E), Mumbai- 400 098, (Maharashtra) India.
- Lots / codes
Lot #: B4000935, Exp 01/17; B4005178, Exp 06/17; B4008730, B4008729, B4008727, B4008724, Exp 10/17; B5001647, B5001648, B5001649, Exp 02/18
- Quantity
- 741.171 kg
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Nationwide and Puerto Rico
- Initiated
- March 11, 2016 · Voluntary: Firm initiated
- Classified
- June 2, 2016
- Reported
- June 8, 2016
- Ended
- August 14, 2017
- How notified
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ceftriaxone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.